REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for aggressive lymphoma that resists standard treatment
Disease control OngoingThis study is testing whether adding a newer immunotherapy drug called glofitamab to a standard chemotherapy combination (GemOx) can help patients with diffuse large B-cell lymphoma that hasn't responded well to initial treatment. The trial will enroll 40 adults whose cancer show…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 02, 2026 04:12 UTC
-
Higher stem cell dose may boost immune recovery after lymphoma treatment
Disease control OngoingThis study investigates whether giving a higher dose of a patient's own stem cells during transplant leads to better immune system recovery and outcomes for people with aggressive lymphoma that has returned or resisted treatment. Participants with relapsed or refractory diffuse l…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC